AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01417689 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Encouragement to attempt eye drop instillation with a specific technique
Description: Encouragement to one of the 2 techniques (open eyes and closed eyes) is accomplished through a standardized educational session designed to take2-5 minutes.
Study NCT03909126 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix administered during gestational diabetes screening
Description: Boostrix administered during gestational diabetes screening
Study NCT03909126 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix administered in high volume obstetric clinic
Description: Boostrix administered in high volume obstetric clinic
Study NCT04719091 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lubricity
Description: Oral spray
Study NCT04719091 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Lubricity
Description: Oral spray
Study NCT03076099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: 1.2 μg/kg Dexmedetomidine was administered intravenously constantly after tracheal extubation.
Study NCT03076099 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: equal volume of normal saline was administered intravenously constantly after tracheal extubation.
Study NCT02432872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: defferent doses of daunorubicin,that is 60mg/m2 for 3 doses compared with 45mg/m2 for 3 doses
Study NCT02432872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin
Description: defferent doses of daunorubicin,that is 60mg/m2 for 3 doses compared with 45mg/m2 for 3 doses
Study NCT02432872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: medium dosage cytarabine（1 g/m2 q12h for 3 days) compared with standard dosage cytarabine(100mg/m2 per day for 6 days)combinated with aclacinomycin（20mg per day for 6 days）for consolidation therapy.
Study NCT02432872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: medium dosage cytarabine（1 g/m2 q12h for 3 days) compared with standard dosage cytarabine(100mg/m2 per day for 6 days)combinated with aclacinomycin（20mg per day for 6 days）for consolidation therapy.
Study NCT01440426 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous connective tissue graft with rotated papilla flap
Description: Subepithelial connective tissue graft harvested from hard palate
Study NCT01440426 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Collagen matrix construct (Mucograft)
Description: Mucograft Collagen Matrix combined with rotated papilla flap
Study NCT01012232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mL ropivacaine 5 mg/mL
Study NCT01012232 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 mL ropivacaine 10 mg/mL
Study NCT02953301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: resminostat
Study NCT02953301 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02448459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COOL-COS
Description: Controlled ovarian stimulation will start on the second or third day of a menstrual cycle: Oral clomiphene citrate: 100 mg/day until the day of the triggering. Oral letrozole: 7.5 mg/day during the first 5 days of the controlled ovarian stimulation.~Corifollitropin Alfa: 100 mcg on the 3rd day of the controlled ovarian stimulation.~The triggering will be performed using leuprorelin 1 mg (subcutaneous).
Study NCT03384745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M1095 (Sonelokimab)
Description: M1095 (Sonelokimab) is a trivalent monomeric nanobody® that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F.
Study NCT03384745 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: M1095 (Sonelokimab)
Description: M1095 (Sonelokimab) is a trivalent monomeric nanobody® that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F.
Study NCT03384745 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains no active drug.
Study NCT03384745 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Secukinumab
Description: Secukinumab is a human immunoglobulin G1 (IgG1) monoclonal antibody that selectively binds IL-17A.
Study NCT01430260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclesonide
Description: 200 ㎍ once daily
Study NCT01430260 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levocetirizine
Description: 5mg once daily
Study NCT05297747 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Apical periodontitis
Description: Radiography of the patients were taken. Blood samples were collected from those patients.
Study NCT05297747 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Chronic periodontitis
Description: Radiography of the patients were taken. Blood samples were collected from those patient
Study NCT03426930 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: self-evaluation of the Body Mass Index
Description: Evaluation of the Body Mass Index before and after the treatment
Study NCT03426930 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self-evaluation of the Body Mass Index
Description: Evaluation of the Body Mass Index before and after the treatment
Study NCT03426930 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-behavioral psychotherapies
Description: Cognitive-behavioral psychotherapies before and after the treatment
Study NCT03426930 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral psychotherapies
Description: Cognitive-behavioral psychotherapies before and after the treatment
Study NCT03139214 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parenting Intervention
Study NCT04217226 — intervention group
Intervention type: DEVICE
Intervention: Perfusion index derived parameters
Description: The PVI and PI will be recorded in the supine position by an anaesthesiologist who was not involved in the further intraoperative monitoring of the patient using Masimo SET (MightySat 9900, Masimo Corporation, Irvine, CA, USA). This device allows bluetooth radio for transfer of parameter data to a smart device. The device will be applied on the index finger of the dominant hand of each patient. It will be applied on the hand that neither contains the venous line nor the blood pressure cuff. Three measurements of PVI and PI on one minute interval will be recorded. We will use the average of these readings.~Dicpleth is defined as the ratio of the height of the dicrotic notch to the height of the systolic peak, measured at end-expiratory time.
Study NCT01430260 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide & Levocetirizine
Description: * Omnaris (ciclesonide) 200 ㎍ once daily~* Levocetirizine 5mg once daily
Study NCT02509728 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: choline supplementation
Description: in addition to standard nutrition: enteral supplementation with 30mg/kg choline chloride for 10 days
Study NCT02509728 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA supplementation
Description: in addition to standard nutrition: enteral supplementation with 60mg/kg DHA for 10 days
Study NCT02509728 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: standard nutrition
Description: standard nutrition
Study NCT02509728 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: standard nutrition
Description: standard nutrition
Study NCT04124861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug free, IS monotherapy and GC combined with IS
Description: Follow-up intervals: Every 3 months (3th, 6th, 9th, 12th, 15th, 18th month).
Study NCT03711773 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group Physical Therapy Classes
Description: Three times weekly, these subjects will have one hour group physical therapy sessions with either a physical therapist, physical therapy assistant, or personal trainer. These sessions will be aimed to improve strength and function in a low-impact setting designed specifically for those with joint pain.
Study NCT04431466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: SOC plus different dosing regimens of Ivermectin
Study NCT00332293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Alternative Formulation Ophthalmic Solution 0.5%
Description: 1 drop into the conjunctival sac of both eyes 3 times a day for 3 days
Study NCT00332293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin hydrochloride ophthalmic solution 0.5% as base
Description: 1 drop into the conjunctival sac of both eyes 3 times a day for 3 days
Study NCT00927810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Study NCT00751374 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: gentamicin
Description: topical gentamicin cream on daily basis
Study NCT00751374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gentamicin cream alternating with mupirocin cream
Description: topical gentamicin cream alternating with mupirocin cream at monthly basis
Study NCT03238950 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Porcine model
Description: participants to conduct training on porcine model
Study NCT03238950 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Synthetic model
Description: participants to conduct training on synthetic model
Study NCT00798889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib dose varies according to the doses allowed in previous protocol. It is given once a day, orally with various schedules depending on the parent protocol
Study NCT04431466 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard treatment for COVID-19
Study NCT02200731 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FAMOS: psychosocial family intervention
Description: The FAMOS intervention consists of a six session manualized psychosocial intervention including videos and tools. Four sessions focus on the parents and two sessions focus on the childhood cancer survivor and its siblings. The intervention is conducted by a psychologist with Cognitive Behavioral Therapy experience
Study NCT03961789 — intervention group
Intervention type: OTHER
Intervention: patients undergoing opioid replacement therapy
Description: patients undergoing opioid replacement therapy
Study NCT03253224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Magnesium group receives magnesium sulfate (50 mg/kg) in 100 mL of normal saline over 15 min during induction of anesthesia, followed by a continuous magnesium sulfate infusion (15 mg/kg/h) until the end of surgery.
Study NCT03253224 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline group receives the same volume of normal saline, administered according to the same method as in the magnesium group.
Study NCT03175770 — intervention group
Intervention type: PROCEDURE
Intervention: transoral radiofrequency Resection in Oropharyngeal Tumor Surgery
Description: Patient of 18 years and older with benign or malign tumor in the oropharynx. The resection is done transorally by radiofrequency
Study NCT02630134 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: These patients receive the Baeta device and take it home
Study NCT04884334 — intervention group
Intervention type: DEVICE
Intervention: VAC-Stent®
Description: treatment with the VAC-Stent®
Study NCT03602417 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flare type stent
Description: Flare type has a wide diameter at proximal portion to prevent stent migration.
Study NCT03602417 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional D-type stent
Description: This stent is an original full covered stent to treat malignant colorectal obstruction.
Study NCT05452655 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidisciplinary Intensive Rehabilitation
Description: The rehabilitation program will last for 6 consecutive weeks and involves the execution of 30 sessions, 5 days a week lasting 160 '/ day each (80' motor; 40 'cognitive and 40' speech therapy rehabilitation) for 3 days a week and 180'/ day (80 'motor; 60' cognitive and 40 'speech therapy rehabilitation) for 2 days a week. The EXP group will receive 18 sessions (3 times a week) of treadmill (20 min), balance exercises and functional reinforcement (20 min). The remaining motor sessions will be defined based on the patient's therapeutic needs.~The cognitive treatment will be proposed both in traditional mode (3 times a week) and through the support of semi-immersive Virtual Reality Rehabilitation System (VRRS) (2 times/week). The VRRS treatment is structured in 2 sessions per week (60 min) for 6 consecutive weeks.~The speech therapy program will include clinical and instrumental evaluations and innovative techniques will be used for the treatment (biofeedback with Vitalstim).
Study NCT05452655 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Muscle-stretching and active mobilization exercises
Description: The control group subjects will undergo a home-based self-treatment program for 40 '/ day for 6 consecutive weeks consisting of muscle-stretching and active mobilization exercises.
Study NCT03339479 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: dielectric property test
Description: Test the dielectric property of resected lung nodules/mass through a touching probe after the lung tissue with nodules/mass has been resected and cut open, which usually takes only 1-5 minutes.
Study NCT03339479 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: frozen pathological examination
Description: And after the dielectric property test, the lung tissue will be sent for frozen pathological examination.
Study NCT03339479 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: final pathological examination
Description: All of the lung nodules/mass will be diagnosed by final pathological examination and recognized as the final diagnosis after surgery.
Study NCT01974167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eldecalcitol
Description: Eldecalcitol 0.75 microgram once daily orally
Study NCT01974167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alfacalcidol
Description: Alfacalcidol 1 microgram once daily orally
Study NCT02926248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Colchicine is an anti-fibrotic and anti-inflammatory drug
Study NCT02926248 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02159131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinyl Estadiol
Description: EE is available as a combination of EE 0.03 mg and LNG 0.15mg, a monophasic oral contraceptive tablet to be taken along with 240 mL water
Study NCT02159131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel
Description: LNG is available as a combination of EE 0.03 mg and LNG 0.15mg, a monophasic oral contraceptive tablet to be taken along with 240 mL water
Study NCT02159131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744
Description: GSK1265744 is available as 30 mg tablet to be taken along with 240 mL water
Study NCT03878732 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Bindex measurement
Description: One time bone density measurement with ultrasound device
Study NCT01314040 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Run in diet
Description: Fully controlled dietary period during 9 days. Participants will receive approximately 15 en% of protein. The amount of protein intake from dairy, meat, and grain will be equal to each other
Study NCT01314040 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High meat protein diet
Description: Fully controlled diet during 7 days. Participants will consume 18 en% protein, mainly from meat.
Study NCT01314040 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High dairy protein diet
Description: Fully controlled dietary intervention during 7 days. Participants will consume 20 en% protein. Mainly from dairy
Study NCT01314040 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High grain protein diet
Description: Fully controlled dietary intervention for 7 days. Participants will consume 20 en% of protein. Mainly from grain
Study NCT01704313 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interrupted
Description: Interrupted suturing technique used aroudn the heel of the vascular anastomosis
Study NCT01704313 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous
Description: Continuous suturing technique used for the anastomosis
Study NCT03243669 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: Standard colonoscopy
Study NCT03327766 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 4-Measurment of serum 25(OH)D3 using Vidas by ELFA meathod.
Description: A specialized test of the 25(OH)D serum level was conducted and the blood samples were collected in the months of November to April. The winter months were chosen intentionally in order to limit the impact of the sun light upon 25(OH)D serum level.The test VIDAS® 25 OH Vitamin D Total was used-enzyme immunoassay with highly fluorescent measurement ELFA. According to the reference values of this method the 25(OH)D \< 20 ng/ml serum levels are considered as deficiency and the serum levels between 20 - 30ng/ml are defined as insufficiency. It's sufficient if the level of 25(OH)D is 30 to 100 ng/ml.
Study NCT03344679 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacaine 0.25%
Description: Bupivacaine 0.25% for PECS block
Study NCT03344679 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Adenosine 12mg
Description: Adenosine 12 mg for PECS block
Study NCT03344679 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Magnesium Sulphate 500 mg
Description: Magnesium sulphate 500 mg for PECS block
Study NCT03228056 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: pain intensity measured in VAS scale
Description: Pain intensity in 0-100 mm VAS scale is measured every 4 hours on standard ruler beginning from the end of the surgery.
Study NCT03228056 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: pain intensity measured in VAS scale
Description: Pain intensity in 0-100 mm VAS scale is measured every 4 hours on standard ruler beginning from the end of the surgery.
Study NCT03838926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trichostatin A
Description: Intravenous Infusion
Study NCT00550485 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: escitalopram
Description: escitalopram 4 mg
Study NCT00388310 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Culture
Description: Culture
Study NCT00388310 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Culture
Description: Culture
Study NCT03907280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1265162 (T1)
Description: oral solution
Study NCT03907280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1265162 (T2)
Description: Solution for inhalation
Study NCT04073602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48-ADC
Description: The eligible patients will be treated with RC48-ADC, an antibody-drug conjugate, 2.0 mg/kg, once every two weeks until investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first).
Study NCT02455648 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESD/EMR plus Cell Sheet
Description: Patients receive ESD/EMR plus CellSheet:~Autologous oral mucosa/buccal-derived epithelial cells, cultured on temperature-sensitive membrane (Cell Sheet) that are inserted 2 weeks later on the occasion of the ESD or EMR
Study NCT02455648 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: ESD/EMR
Description: only ESD/EMR: Autologous oral mucosa/buccal-derived epithelial cells, cultured on temperature-sensitive membrane (Cell Sheet) but NOT used for insertion in the patient during/after ESD/EMR two weeks later
Study NCT03595579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXS-05
Description: AXS-05 taken twice daily for 6 weeks.
Study NCT03595579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: Bupropion taken twice daily for 6 weeks.
Study NCT03705208 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Youth First Curriculum
Description: A 25 session emotional resilience and health curriculum designed for 7th and 8th grade students.
Study NCT03099993 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Measurement of maximal forces of elbow pronosupination and flexion-extension
Description: Maximal forces of elbow pronosupination and flexion-extension will be measured with a portable dynamometer.